INVESTABOT
Equity Research
XNAS · PHARMACEUTICAL PREPARATIONS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Agios Pharmaceuticals posted Q1 2026 revenue of $20.7 million, up 137.7% from $8.7 million in Q1 2025, driven by the U.S. launch of AQVESME in thalassemia.
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 6,455,997 | $239,582,050 | 12.2% | 8/7/2026 |
| BlackRock | 4,859,002 | $209,520,165 | — | 8/13/2024 |
| BlackRock | 5,754,957 | $194,690,195 | 9.9% | 5/13/2026 |
| Vanguard Group | 5,594,353 | $152,278,288 | — | 1/29/2026 |
| BlackRock | 5,235,429 | $142,508,377 | — | 2/12/2026 |
| State Street | 3,533,633 | $131,144,972 | 5.0% | 8/7/2026 |
| DE Shaw | 3,107,005 | $115,300,956 | 15.9% | 8/14/2026 |
| State Street | 3,364,879 | $113,719,376 | 8.3% | 5/15/2026 |
| DE Shaw | 2,681,169 | $90,703,947 | 44.0% | 5/15/2026 |
| State Street | 3,108,145 | $84,603,707 | — | 2/13/2026 |
| DE Shaw | 1,861,286 | $50,664,205 | — | 2/17/2026 |
| Citadel Advisors | 1,608,868 | $43,793,387 | — | 2/17/2026 |
| Goldman Sachs | 1,150,932 | $42,711,087 | 40.8% | 8/14/2026 |
| Morgan Stanley | 963,256 | $35,746,487 | -0.4% | 8/13/2026 |
| Citadel Advisors | 913,187 | $33,888,370 | 18.7% | 8/14/2026 |
| Morgan Stanley | 967,525 | $32,731,410 | 8.2% | 5/15/2026 |
| Goldman Sachs | 1,033,974 | $28,144,772 | — | 3/25/2026 |
| Goldman Sachs | 817,676 | $27,661,979 | -20.9% | 5/15/2026 |
| Citadel Advisors | 769,413 | $26,029,242 | -52.2% | 5/15/2026 |
| AQR Capital | 684,340 | $25,395,858 | 1779.5% | 8/14/2026 |